These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15361504)

  • 1. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.
    Veldt BJ; Saracco G; Boyer N; Cammà C; Bellobuono A; Hopf U; Castillo I; Weiland O; Nevens F; Hansen BE; Schalm SW
    Gut; 2004 Oct; 53(10):1504-8. PubMed ID: 15361504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.
    Kasahara A; Tanaka H; Okanoue T; Imai Y; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
    J Viral Hepat; 2004 Mar; 11(2):148-56. PubMed ID: 14996350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.
    Chavalitdhamrong D; Tanwandee T
    World J Gastroenterol; 2006 Sep; 12(34):5532-5. PubMed ID: 17006994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
    Formann E; Steindl-Munda P; Hofer H; Jessner W; Bergholz U; Gurguta C; Ferenci P
    Aliment Pharmacol Ther; 2006 Feb; 23(4):507-11. PubMed ID: 16441471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tokuda A; Horiguchi Y; Nakano H; Honda T; Nakano S; Hayashi K; Katano Y; Nakano I; Hayakawa T; Nishimura D; Kato K; Imada K; Imoto M; Fukuda Y;
    J Viral Hepat; 2000 Nov; 7(6):414-9. PubMed ID: 11115052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
    Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminoadamantanes for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
    Wang X; Gao F; Yuan G; Shi K; Huang Y; Chen Y; Qiu R; Sun L; Liu J; Hu C; Zhou Y
    J Viral Hepat; 2016 Dec; 23(12):971-976. PubMed ID: 27453300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
    Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitazoxanide for chronic hepatitis C.
    Nikolova K; Gluud C; Grevstad B; Jakobsen JC
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD009182. PubMed ID: 24706397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.
    Trapero-Marugán M; Mendoza J; Chaparro M; González-Moreno L; Moreno-Monteagudo JA; Borque MJ; Moreno-Otero R
    World J Gastroenterol; 2011 Jan; 17(4):493-8. PubMed ID: 21274379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
    Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
    Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
    Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.
    Bruno S; Battezzati PM; Bellati G; Manzin A; Maggioni M; Crosignani A; Borzio M; Solforosi L; Morabito A; Ideo G; Podda M
    J Hepatol; 2001 May; 34(5):748-55. PubMed ID: 11434622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
    Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study.
    Wedemeyer H; Reimer J; Sandow P; Hueppe D; Lutz T; Gruengreiff K; Goelz J; Christensen S; Pfeiffer-Vornkahl H; Alshuth U; Manns MP
    Liver Int; 2017 Oct; 37(10):1468-1475. PubMed ID: 28247572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.